IT Tech Packaging, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.3M
- Price
- $0.1712
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.17%
- Volume
- 161.4K
About
IT Tech Packaging, Inc., through its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. It also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, the company produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. IT Tech Packaging, Inc. was founded in 1996 and is headquartered in Baoding, the People's' Republic of China.
Quick stats
Shares outstanding17.0M
Computed float16.4M
Float / shares96.8%
Key info
SectorBasic Materials
IndustryPaper, Lumber & Forest Products
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001358190
Websitehttps://www.itpackaging.cn
AI Summary
AI-generated1/3
majorpress release
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.